slides · global inventory
Image
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 119,566
Current window 84,541-84,570
Pages 3,986
Rows per page 30
Component
84,541-84,570 of 119,566
13
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations 1 hit
01
Includes company logo, tagline, date, and ticker symbol.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
07
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
08
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
09
Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the difficulty of treatment compliance.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
11
Includes a biological process diagram showing intracellular vs plasma metabolism.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · SolutionLoop · Mece Breakdown1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
27
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
39
The slide uses a split-screen layout: left side is market sizing/segmentation, right side is a 2x2 strategic framework for launch execution.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
01
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Beat · Attention1 hit
06
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
07
The slide uses a linear process flow to demonstrate the progression of a customer engagement.Aeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Loop · Aha Moment1 hit
10
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Beat · DesireLoop · Why Now1 hit
11
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Loop · Why Now1 hit
12
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations 1 hit
14
Aeva | Results Presentation Deck | 14 slidesAeva | Results Presentation Deck | 14 slides · Aeva
Shareholder letter Investor relations Beat · Action1 hit
01
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
07
Includes a boxed warning disclaimer at the bottom.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
11
The slide includes a mandatory boxed warning disclaimer at the bottom.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
13
Includes product branding, dosage options, and a bar chart showing revenue growth.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
14
Includes a callout regarding COVID-19 impact on 2020 sales.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
17
Includes a medical illustration of brain pathways related to wakefulness and neurotransmitters.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
18
Includes a molecular visualization of the Orexin 2 receptor.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
25
The slide uses a human body diagram to map clinical responses (CR, PR, uPR) across various cancer types.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
32
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
01
Allbirds | Investor Presentation Deck | 14 slidesAllbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations 1 hit
03
Allbirds | Investor Presentation Deck | 14 slidesAllbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations 1 hit
04
Includes a financial table comparing Q4 2022 and Full Year 2022 results.Allbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
05
Allbirds | Investor Presentation Deck | 14 slidesAllbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
06
Uses a 'Where we are today' vs 'Where we are going' structure to frame the company's evolution.Allbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · RoadmapLoop · Why Now1 hit